Frank Zycinski - Jan 29, 2024 Form 4 Insider Report for PLEXUS CORP (PLXS)

Signature
/s/ Frank Zycinski, by Kate A. Gitter, Attorney-in-Fact
Stock symbol
PLXS
Transactions as of
Jan 29, 2024
Transactions value $
$0
Form type
4
Date filed
1/31/2024, 04:10 PM
Previous filing
Aug 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PLXS Common Stock, $.01 par value 0 Jan 29, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLXS Restricted Stock Units Award +1.95K 1.95K Jan 29, 2024 Common Stock, $.01 par value 1.95K Direct F1
transaction PLXS Performance Stock Units Award +1.84K 1.84K Jan 29, 2024 Common Stock, $.01 par value 1.84K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit granted under the Plexus Corp. 2016 Omnibus Incentive Plan, which qualifies under Rule 16b-3, represents a contingent right to receive one share of Plexus Corp. common stock. The Restricted Stock Units vest on January 29, 2027.
F2 Each Performance Stock Unit ("PSU") granted under the Plexus Corp. 2016 Omnibus Incentive Plan, which qualifies under Rule 16b-3, represents a contingent right to receive one share of Plexus Corp. common stock if certain conditions are satisfied. Vesting of 860 PSUs is dependent on the relative total shareholder return ("TSR") of Plexus Corp.'s common stock as compared to companies in the S&P 400 Index and vesting of the remainder is based on goals related to economic return ("ER") during the three-year performance period. The target number of PSUs that may be earned is reported above. The reporting person may earn up to 150% of the targeted amount that is based on TSR and up to 200% of the targeted amount that is based on ER.